UroMed sells softpatch technology to Procter & Gamble:
This article was originally published in Clinica
Executive Summary
UroMed, which manufactures interventional urological devices, has sold the non-prescription rights to its Softpatch technology to Procter & Gamble for $3.3 million in cash and $600,000 spread over the next four years. The Norwood, Massachusetts-based company's primary focus is in prostate cancer. Its lead product is the CaverMap nerve-mapping device for use during prostate surgery to prevent nerve severance.